Form 4: Avanos Medical SVP, General Counsel Mojirade James Reports Acquisition of Shares and Stock Options

Mojirade James, SVP, General Counsel of Avanos Medical, reports the acquisition of restricted share units and stock options.

Summary

• On March 7, 2025, Mojirade James, SVP, General Counsel of Avanos Medical, acquired 19,201 shares of common stock and 41,199 employee stock options.
• The common stock was acquired at a price of $0.
• The employee stock options have an exercise price of $15.24 and expire on March 7, 2035.
• The restricted share units (TRSUs) will vest in three equal installments on March 7, 2026, March 7, 2027, and March 7, 2028.
• The employee stock options will vest 30% on March 7, 2026, 30% on March 7, 2027, and 40% on March 7, 2028.
• Following the reported transactions, James directly owns 88,218 shares of common stock and 41,199 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be interpreted as a sign of confidence, but it doesn't provide enough information to strongly skew positive or negative.

Positives

• The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares and stock options by a company executive can positively influence shareholder sentiment.

Key Dates